Business Wire

VA-DXC-TECHNOLOGY

18.3.2020 14:02:17 CET | Business Wire | Press release

Share
DXC Technology’s Integrated Patient-Centered Care Solution Creates New Opportunities for Interoperability and Patient Engagement

DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.

The healthcare industry is experiencing a value-based shift of epic proportions, driven by key external trends like an aging population; the proliferation of chronic diseases; rising healthcare costs; staffing shortages; and digital citizenship creating more informed patients. To elevate the patient experience, improve individual outcomes and create a healthier population, healthcare leaders are seeking new business and integrated care models that merge healthcare and life sciences while empowering patients and providers alike.

To help solve these challenges, DXC Patient-Centered Care provides advanced patient-engagement tools that offer convenient care from anywhere, via phone or tablet, at an affordable price. Backed by DXC’s interoperability, analytics and security products, the solution enables providers to access a continuous stream of patient-care data, helping them put the patient first throughout the continuum of care.

“In the age of ‘Dr. Google’ and same-day Amazon deliveries, patients are increasingly more demanding. They will no longer tolerate half-day waits for discharge instructions that could be delivered in seconds via a chatbot, or receive test results by snail mail when they could be viewed immediately on a mobile app. They expect better value and engagement from caregivers, driving the industry to move from traditional care-delivery models toward a patient-centered journey of care,” said Andrea Fiumicelli, vice president and general manager, Healthcare and Life Sciences , DXC Technology. “Our new Patient-Centered Care solution combines DXC’s industry expertise and leading healthcare technology to equip providers with custom-built, next-generation and coordinated care solutions.”

“The future of connected healthcare is centered around collaboration and care, and today’s busy providers need to find innovative ways to connect with their patients within and beyond the walls of a hospital or clinic,” said Dr. Michael Dahlweid, who recently joined DXC as its new global chief medical officer. “Our goal is to enable care teams to share health information across multiple systems, channels, practices and infrastructures, and aggregate it into a secure, consolidated view of the patient’s history of care. This persona-based access to real-time health data will allow clinicians to make the best possible decisions for their patients’ treatment. With speed, scale, flexibility and continuous innovation, DXC Technology prepares traditional healthcare organizations to become major digital-health enablers.”

The DXC Healthcare Portfolio

Patient-Centered Care is the newest solution in DXC’s extensive healthcare portfolio that is transforming the healthcare industry. The portfolio also includes:

  • DXC Open Health Connect , a healthcare platform that helps improve healthcare outcomes by creating a connected ecosystem for patients, providers and payers.
  • DXC Healthcare Cloud , a cloud-based solution that reduces complexity and risk while allowing approved parties to securely access applications and data 24/7.
  • DXC Healthcare Security Services — for which DXC was recently named a leader in the Everest Group PEAK Matrix Assessment 2020 — to help healthcare providers quickly identify and respond to threats, protect data and patient privacy, and securely manage patient identities stored on-premise or in the cloud.
  • DXC Health360 , a cloud-based solution that enables providers and payers to personalize care experiences, deliver quality and increase customer loyalty at a lower cost.
  • DXC Life Sciences solutions , which give life sciences organizations — including all 12 U.S. Fortune 500 pharmaceutical companies — the tools they need to accelerate innovation, improve operational efficiencies and reduce time to market for new therapies, devices and medicines.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

# # #

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release

The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight

Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release

Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices

Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release

Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot

Freedom Holding Corp. Works With Ant International’s Antom to Simplify Online Shopping From China for Kazakhstan Consumers23.7.2026 07:30:00 CEST | Press release

Freedom Bank SuperApp to be promoted as a payment option on China’s leading e-commerce platforms through Antom On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722367119/en/ From left to right: Timur Turlov, CEO of Freedom Holding Corp., Leiming Chen, Senior Vice President and Chief Sustainability Officer of Ant International Antom will promote Freedom Bank SuperApp as a supported payment option on China’s leading e-commerce platforms. This move aims to create a seamless cross-border online shopping experience, allo

Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year23.7.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix. Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology. Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ra

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye